FDG-PET imaging in the management of non-small-cell lung cancer

Annals of Oncology

Volumn 13, Issue 3, 2002, Pages 357-360

  Salminen, E ^a   Mac Manus, M ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

FDG PET; Non small cell lung cancer; Outcome; Staging; Treatment

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PLATINUM DERIVATIVE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER STAGING; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENDER; GERMANY; HUMAN; IMAGING SYSTEM; LUNG NON SMALL CELL CANCER; MALE; MEDICAL DECISION MAKING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; WESTERN HEMISPHERE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; SCINTISCANNING;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0036516734     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf106     Document Type: Review

References (36)

1. Non-small-cell lung cancer - Stalemate or progress?
2. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small cell lung carcinomas: Are these carcinomas candidates for video-assisted lobectomy?
3. Sites of recurrence in resected stage I non-small cell lung cancer. A guide for future studies
4. Radiotherapy for non-small-cell bronchial cancers: Definitions of volumes, patient selection. Recommendations of the International Association for the Study of Lung Cancer (IASLC)
5. Survival and prognosis following resection of primary non-small-cell bronchogenic carcinoma
6. Gross tumor volume is an independent predictor of survival in non-small cell lung carcinoma patients treated with conformal radiotherapy
7. Lung cancer proliferation correlates with F-18 fluorodeoxyglucose uptake by positron emission tomography
8. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer
9. Evaluation of fluorine-18-fluorodeoxyglucose whole body emission tomography imaging in the staging of lung cancer
10. Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography
11. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small-cell lung cancer
12. Metastases from non-small-cell lung cancer: Mediastinal staging in the 1990s meta analytic comparison of PET and CT
13. Detection of extrathoracic metastases by positron emission tomography in lung cancer
14. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography
15. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small-cell lung cancer
16. FDG-PET imaging for the staging and follow-up of non small cell lung cancer
17. Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumours. Basis for discussion of the German Concensus Conference on PET in Oncology
18. Roentgenographic evaluation of mediastinal nodes for preoperative assessment in lung cancer
19. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm) and large (>3 cm) lymph node lesions
20. Accuracy of positron emission tomography with fluorine-18-fluoro-deoxyglucose
21. How useful is positron emission tomography for lymphnode staging in non-small cell lung cancer?
22. Metabolic staging of lung cancer
23. Preoperative staging of non-small-cell lung cancer with positron-emission tomography
24. High rate of detection of unsuspected metastases by PET in apparent stage III NSCLC: Implications for radical radiation therapy
25. FDG-PET staging in radical radiotherapy candidates with non-small cell lung cancer: Powerful correlation with survival and high impact on treatment
26. Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases
27. The impact of 18 F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small-cell lung cancer
28. Staging by positron emission tomography predicts survival in patients with non-small-cell lung cancer
29. Early F-18 FDG-PET response to radical chemoradiotherapy correlates strongly with survival in unresectable non-small-cell lung cancer
30. Measurement of clinical and subclinical tumour response using FDG and PET: Review and 1999 EORTC recommendations
31. Reimbursement and technology assessment for positron imaging
32. Decision tree sensitivity analysis for cost effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma
33. Lung cancer and positron emission tomography with fluorodeoxyclocose
34. Cost-effectiveness of PET in the management algorithms of lung tumours: Comparison of health economic data
35. Being equipped for clinical PET
36. Impact of FDG-PET on the management of non-small-cell lung cancer